摘要 |
An AIDS therapeutic composition comprising, as essential effective components which bring about a human immunodeficiency virus protease inhibition action, (R)-N-(1,1-dimethylethyl)-3-[(2S,3S)-2-hydroxy-3-[(R)-2-(5-isoquinolyloxyacetyl)amino-3-methylthiopropanoyl] amino-4-phenylbutanoyl]-1,3-thiazolidine-4-carboxyamide (KNI-272) and a compound selected from the group consisting of N-(1,1-dimethylethyl)-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-{[N-(2-quinolylcarbonyl)-L-asparaginyl]amino}butyl]-(4aS, 8aS)-isoquinoline-3(S)-carboxyamide (Saquinavir), 5S-(5R*, 8R*, 10R*,11R*)-10-hydroxy-2-methyl-5-(1-methylethyl)-1-[2-(1-methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenyl methyl)-2,4,7,12-tetrazatridecane-13-hydroxy acid, 5-thiazolylmethyl ester (Ritonavir), [1(1S, 2R),5(S)]-2,3,5-trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-[2-{[(1,1-dimethylethyl) amino]carbonyl}-4-(3-pyridinylmethyl)-1-p iperazinyl]-2-(phenylmethyl)-D-erythropentonamide (Indinavir), and [3S-2(2S*, 3S*), 3 alpha , 4a beta , 8a beta ]]-N-(1,1-dimethylethyl)-decahydro-2-[2-hydroxy-3-(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-3-isoquinolinecarboxamide (Nelfinavir), in an amount and proportion in which a synergistic treatment effect can be exhibited. |